Yale University

New Haven, Connecticut
Sterling Professor of Chemistry


Dr. Jorgensen’s research focuses on the discovery of drugs for cancer chemotherapy. He is a renowned expert in developing and applying the requisite methodology and computer software for computer-aided drug design. His team of experts are designing drugs that bind tightly to enzymes (protein molecules that catalyze reactions) involved in aberrant cell proliferation. The tight binding causes the enzymes to stop functioning, the cancer cells to stop reproducing, and the tumors to shrink. Such drugs are called enzyme inhibitors. Specifically, his research has sought inhibitors of an enzyme called fibroblast growth factor receptor 1 kinase (FGFR1 kinase). Aberrant FGFR kinase activity has been implicated in numerous cancers including breast cancer, human pancreatic cancer, astrocytomas, salivary gland adenosarcoma, Kaposi’s sarcoma, ovarian cancer, and prostate cancer. Therefore, discovery of inhibitors of FGFR1 kinase has substantial potential therapeutic value.

His team computationally modeled millions of compounds that might be possible FGFR1 kinase inhibitors and 23 compounds were purchased and experimentally tested. Two of the compounds showed some inhibitory activity towards FGFR1 kinase and his team focused on improving the potency of the compounds and their chemical properties to make them more likely to become drugs. Their work required the preparation (“synthesis”) of modified versions, “analogs”, of the initial “lead” compounds. They explored various changes in the series of thienopyrimidinone compounds and simplified the structures to only pyrimidinones which are uncommon as kinase inhibitors and were active at low micromolar concentrations. Future research will focus on enhancing the activity of these compounds and testing for selectivity in inhibiting other kinases.


Dr. William Jorgensen received his B.A. from Princeton University and his Ph.D. from Harvard University. In 1975, he first joined the faculty at Purdue University and in 1990, he joined the faculty at Yale University as the Whitehead Professor of Chemistry. He served as Director, Division of Physical Sciences & Engineering and he is currently the Sterling Professor of Chemistry.

From 2005 to 2010 at Yale University, Dr. Jorgensen co-directed the NFCR Center for Anti-Cancer Drug Design and Discovery with Director and NFCR-supported scientist, Dr. Alanna Schepartz. He is an elected member of the National Academy of Sciences and a Fellow of the American Chemical Society. Dr. Jorgensen is the recipient of numerous awards including; the ACS Award for Computers in Chemical and Pharmaceutical Research; Award in Computational Biology – International Society for Quantum Biology and Pharmacology; the Hildebrand Award in the Theoretical and Experimental Chemistry of Liquids (ACS); and the Tetraheron Prize.

He has published over 400 articles in the field of computational chemistry. He and his lab have developed software and computer modeling programs for drug design including TIP3P and TIP4P water models, the OPLS force field, and on free-energy perturbation theory for modeling reactions and molecular recognition in solution. Dr. Jorgensen’s service to the community includes numerous advisory boards in government and industry and journal editorial boards. He has been the Editor of the ACS Journal of Chemical Theory and Computation since its founding in 2005.

Related Content

Research Highlight: Preventing Breast Cancer Brain Metastasis

National Foundation for Cancer Research funded researcher Dr. Daniel A Haber recently unearthed an exciting discovery that may add years to the lives of late-stage breast cancer patients. Dr. Haber is fascinated by understanding drug resistance on a deeper level by studying individual tumor cells in patients’ blood. In December 2020, Dr. Haber and his team shared their exciting findings on how brain metastasis, or the spread of cancer to the brain, may be prevented. Brain metastases occur in about 10% of all patients with cancer and in as many as a third of women with advanced metastatic breast cancer. Though experts have made great strides in suppressing the spread of cancer, there is still little known about the cellular pathways that enable cancer cells to selectively grow in the brain; that is, until Dr. Haber and his research team identified a signaling pathway which appeared significantly more active in brain metastases from breast cancer. “We were looking for what properties of some breast cancer cells made it possible for the cells to grow in the brain, which is a rare but often deadly complication of breast cancer,” Dr. Haber explained. “We weren’t sure what we would find. In a way that’s what makes the discovery process so exciting.” The research commenced approximately 10 years ago while investigating circulating tumor cells (CTCs). As their research progressed, the team homed in on a specific signaling pathway named HIF1A. Using cells from women with breast cancer, the team observed how these cells acted in animal models. It was discovered that if HIF1A was suppressed, the rate of proliferation (or rapid growth) was reduced. Simply put, blocking the HIF1A signaling pathway could reduce the rate of brain metastasis or even prevent it all together. “HIF1A is not specific to brain metastasis, since it’s a very broadly activated pathway in many cancers,” Dr. Haber began. “However, it appears to be more active in brain metastases from breast cancer than in primary breast cancers, and that may help explain what makes these metastases to the brain so unique and so difficult to treat.” The pathway identified in this research is already well known in the cancer world, however its special relevance to the brain was not known until now. Theoretically, a drug could be developed to suppress HIF1A and, in turn, prevent the spread of cancer. While a very promising discovery, Dr. Haber explains that there is far more work to be done. “There are a few HIF1A suppressing drugs now being tested in clinical trials for other indications,” Dr. Haber said, “However, we would have to expand this to multiple different models and systems before we could contemplate an intervention.” In regard to the length of time it takes to have a discovery such as this transitioned to mainstream treatment, Dr. Haber explains that it “depends on the discovery, its potential applications and some ‘luck’.” While the process from discovery to clinical treatment is getting faster all the time, it is likely going to take five to ten years before this finding is implemented into treatment. As for Dr. Haber, he has already planned plenty of work […]

Genetic Testing: Learning More About Your Cancer Risk

Genetic testing can be an important tool in helping patients learn about their inherited cancer risk, but the results are not always as clear as patients might expect. Just as traits such as hair color and eye color can be passed down from parents to their children, so too can the risk for developing certain types of cancer. Scientists know that certain inherited gene mutations — small changes in a person’s DNA — can increase a person’s risk for developing diseases such as breast cancer, ovarian cancer, and colon cancer. Genetic testing examines a person’s DNA to determine if such mutations are present, helping patients better understand their cancer risk and, in some cases, allowing them to take charge of their health before receiving a devastating diagnosis. Understanding the Basics of Genetic Testing Only five to 10 percent of all cancers are believed to be tied to an inherited gene mutation.1 Genetic testing can help determine whether an individual has inherited a specific gene mutation (or mutations) that put him or her at higher risk for developing certain cancers. Most genetic tests require a small blood sample from the patient, but some tests can be performed using urine, saliva, or a cheek swab. The sample is sent to a special laboratory and results are usually provided to the patient’s doctor or genetic counselor within several weeks.2 Genetic testing can return one or a combination of the following results: Positive: The laboratory identified a genetic mutation that is associated with an inherited cancer risk.2 Negative: The laboratory did not find the specific genetic mutation (or mutations) that the test was designed to detect.2 Inconclusive: The laboratory was not able to determine whether a specific genetic mutation (or mutations) was present in the sample provided.2 Variance of Uncertain Significance: The laboratory identified a genetic mutation that has not been previously associated with cancer.2 No test can provide exact answers about a person’s inherited cancer risk. Genetic testing can tell you whether a specific genetic mutation is present in your DNA, but it cannot tell you for certain that you will develop the disease associated with that mutation later in life.3 Knowing Your Cancer Risk: Is Genetic Testing Right for You? Doctors often only recommend genetic testing for patients whose families have a history of certain cancers or patterns of cancer. According to the American Cancer Society, people who meet the following criteria might consider genetic testing: Cancer diagnoses in multiple first-degree relatives, including parents, siblings, or children1 Numerous relatives on one side of the family who have been diagnosed with the same cancer1 Family history of cancers linked to a single gene mutation, such as breast cancer, ovarian cancer, or pancreatic cancer1 Family member(s) who has been diagnosed with more than one type of cancer1 Family member(s) who has been diagnosed with cancer at a younger age than typically seen for that cancer, such as colon cancer1 Close relatives who have been diagnosed with cancers linked to rare hereditary cancer syndromes, such as Hereditary Breast & Ovarian Cancer Syndrome (HBOC), Cowden Syndrome, or Lynch Syndrome1 Family member(s) who has been diagnosed with […]

Sarcoma: The Young Person’s Cancer?